Genfit initiated with an Overweight at Barclays. Barclays analyst Geoff Meacham started Genfit with an Overweight rating and $55 price target. Despite the challenges in nonalcoholic steatohepatitis, Genfit's pipeline offers "compelling opportunities," which creates an attractive risk/reward profile for the stock, Meacham tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2895023
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.